1.22BMarket Cap-327.67P/E (TTM)
10.190High9.755Low751.93KVolume10.180Open10.080Pre Close7.43MTurnover0.77%Turnover Ratio983.00P/E (Static)124.14MShares23.22052wk High-7.31P/B964.21MFloat Cap7.33052wk Low--Dividend TTM98.09MShs Float26.500Historical High--Div YieldTTM4.32%Amplitude7.330Historical Low9.877Avg Price1Lot Size
Indivior Stock Forum
Unexpected FDA Delay: Indivior's SUBLOCADE Label Changes Face Setback Despite Clean Review
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
RICHMOND, Va., Oct. 10, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance.
• Group now sees lower than expected Q3 2024 and FY 2024 SUBLOCADE net revenue (NR) from a combination of faster initial adoption among treatment providers of the...
No comment yet